Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
ConclusionsThese results indicate the viability of TIL ACT for refractory ovarian cancer by allowing for the large expansion of anti-tumor TIL in a short time and consistent manner.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Immunotherapy | Ovarian Cancer | Ovaries | Study